Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in headtohead trial
Dec 04, 2024
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
https://www.cnbc.com/2024/12/04/eli-lilly-zepbound-causes-more-weight-loss-than-novo-nordisk-wegovy-trial.html
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service